At-home testing expansion Leverage Tasso’s at-home blood sampling capabilities and ongoing partnerships (ARUP, Thriva, Neurogen, SheMed) to position Seller as a scalable remote diagnostics and clinical research solution for healthcare systems, CROs, and biotech firms seeking convenient patient-friendly testing.

Clinical research focus Target pharmaceutical and academic research groups looking to decentralize trials and improve participant retention through painless, bedside-to-home sampling, aligning with Tasso’s momentum in developing at-home testing services and ARUP collaborations.

Doping and compliance Capitalize on participation in the 2026 Olympic Winter Games with secure, virtually painless anti-doping tech to approach sports organizations, federations, and event organizers needing reliable, athlete-friendly testing solutions.

Membrane and brain health adjacents Explore partnerships with neurohealth and biomarker ecosystems (e.g., Neurogen) to supply convenient sampling for memory-related diagnostics, expanding into cognitive health monitoring programs and memory clinics.

Funding and growth signals Position Tasso for strategic collaborations with device manufacturers, CROs, and health tech investors by highlighting strong revenue trajectory, substantial funding, and a clear pathway to scale through co-development deals and grant support.